Screener
Veracyte VCYT Product revenue — Other cost
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:OtherCostOfOperatingRevenue.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cost of product revenue: | ||
| Product costs | 1,401 | 109 |
| License fees and royalties | 313 | 324 |
| Other cost of product revenue (2) | 174 | 792 |
| Allocation of facilities and IT expenses | 3 | 197 |
| Total cost of product revenue | 1,891 | 1,422 |
| Cost of biopharmaceutical and other revenue: | ||
| Compensation expense | — | 1,240 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's product revenue — other cost?
- Veracyte (VCYT) reported product revenue — other cost of $174K in Q1 2026.
- How has Veracyte's product revenue — other cost changed year-over-year?
- Veracyte's product revenue — other cost decreased by 78.0% year-over-year, from $792K to $174K.
- What is the long-term trend for Veracyte's product revenue — other cost?
- Over 3 years (2022 to 2025), Veracyte's product revenue — other cost has grown at a 63.1% compound annual growth rate (CAGR), from $771K to $3.35M.
- What does product revenue — other cost mean?
- This metric aggregates miscellaneous direct costs related to the production of goods that do not fall into standard categories like materials or labor. It captures secondary operational expenses necessary to maintain product availability and quality within the segment. Analyzing this helps identify hidden operational overheads that impact the segment's overall cost structure.
Ask your AI about Veracyte's product revenue — other cost.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude